Čes. slov. farm. 2015, 64(1):25-30 | DOI: 10.36290/csf.2015.005
Alzheimer's disease: cost cuts call for novel drugs development and national strategy
- 1 University of Hradec Králové, Faculty of Informatics and Management, Department of Economics, Hradec Králové, Czech Republic
- 2 University of Hradec Králové, Center for Basic and Applied Research, University Hospital Hradec Králové, Biomedical Research Center, Hradec Králové, Czech Republic
Mental health affects the quality of life for a large number of individuals and family members. Currently, globally costs for people with dementia amount to more than 1% of gross domestic product (GDP). In the future, the growth of expenditure is expected with regard to the fact that the population of developed countries is aging and the dementia is closely associated with increasing age. It is evident that governments have to allocate adequate financial, material and human resources to address a health problem on this scale. The purpose of this article is to explore the current state of treatment and care of patients suffering from Alzheimer's disease (AD), analyze direct and indirect health care costs resulting from this disease. In addition, the authors of this article draw attention to the implementation of astrategic plan which would handle all the aspects of AD, including the research of drugs development since nowadays there are not still many drugs which would improve AD patients' state, particularly in the early phases, as well as there does not exist any well-functioning national strategic plan in the Czech Republic which would bring a radical improvement in reducing the effects of AD.
Keywords: Alzheimer's disease; costs; treatment; strategic plan
Grants and funding:
This research was supported by the project Excellence 2015 and internal research "Economic and managerial aspects of processes in biomedicine" (University of Hradec Kralove, Faculty of Informatics and Management).
Received: February 28, 2015; Accepted: April 7, 2015; Published: January 1, 2015 Show citation
References
- MPSV. Preparing for aging. Portal of the Ministry of Labour and Social Affairs 2008; Available from http://www.mpsv.cz/cs/2856 (cited 2014 June 23).
- European Commission. The impact of ageing on public expenditure: projections for the EU25 Member States on pensions, health care, long-term care, education and unemployment transfers. 2006. The report of the Economic Policy Committee and the Directorate General. 2006. http://www.worldbank.org/en/news/feature/2013/01/17/the-eu-11-in-an-aging-europe (cited 2015 March 23).
- Eurostat: Population structure and ageing. 2014. http://ec.europa.eu/eurostat/statistics-explained/index.php/Population_structure_and_ageing (cited 2015 March 23).
- Association of Independent Unions of the Czech Republic. Materials regular meeting of the 96th Plenary Session of 23rd February 2012. http://www.asocr.cz/cz/portal/dokumenty/tripartita/materialy-na-radne-zasedani-96-plenarni-schuze-rhsd-cr-dne-23-unora-2012-526.htm. (cited 2014 June 23)
- Ministry of Health of Czech Republic. Health 2020: Framework summary measures [online] 2013. file:///C:/Users/Maresova/ Downloads/WHO_Zdrav%C3%AD_2020_P%C5%99eklad_CZ.pdf (cited 2014 June 23)
- Mega M. S., Cummings J. L., Fiorello T., Gornbein J. The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996; 46(1), 130-135.
Go to original source...
Go to PubMed...
- Opara J. A. Activities of daily living and quality of life in Alzheimer disease. J. Med. Life 2012; 5(2), 162-167.
- Maresova P., Mohelska H., Kuca K. Cooperation Policy of Rare Diseases in the European Union. 5th ICEEPSY International Conference on Education & Educational Psychology 2015; 171, 1302-1308.
Go to original source...
- Maresova P., Tomaskova H., Kuca K. The Use of Simulation Modelling in the Analysis of the Economic Aspects of Diseases in Old Age. EBES Conference Eurasia Business and Economics 2014; In press.
- Castro D., Dillon C., Machnicki G., Allegri R. The economic cost of Alzheimer's disease: family or public-health burden? Dement. Neuropsychol. 2010; 4, 262-267.
Go to original source...
Go to PubMed...
- Gervès C., Chauvin P., Bellanger M. M., Meidani A. Evaluation of full costs of care for patients with Alzheimer's disease in France: The predominant role of informal care. Health Policy 2014; 116, 114-122.
Go to original source...
Go to PubMed...
- Schwarzkopf L., Menn P., Kunz S., Holle R., Lauterberg J., Marx P., Mehlig H., Wunder S., Leidl R., Donath C., Graessel E. Costs of care for dementia patients in community setting: An analysis for mild and moderate disease stage. Value in Health 2011; 14, 827-835.
Go to original source...
Go to PubMed...
- Getsios D., Blume S., Khajak J. I., Maclaine G. and Hernández L. An economic evaluation of early assessment for Alzheimer's disease in the united kingdom. Alzheimer's 2012; 8, 22-30.
Go to original source...
Go to PubMed...
- Wang G, Cheng Q, Zhang S, et al. Economic impact of dementia in developing countries: an evaluation of Alzheimer-type dementia in Shanghai, China. J. Alzheimer Dis. 2008; 15, 109-115.
Go to original source...
Go to PubMed...
- Mangialasche F., et al. Alzheimer's disease: clinical trials and drug development. Lancet Neurol. 2010; 9, 702-716.
Go to original source...
Go to PubMed...
- Hyde Ch., Peters J., Bondi M., et al. Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model. Age and Ageing 2013; 42, 14-20.
Go to original source...
Go to PubMed...
- Feldman H. H., Lane R. Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 2007; 78, 1056-1063.
Go to original source...
Go to PubMed...
- Mowla A., Mosavinasab M., Haghshenas H., Haghighi A. B. Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double-blind, placebo-controlled clinical trial. J. Clin. Psychopharmacol. 2007; 27, 484-487.
Go to original source...
Go to PubMed...
- Winblad B., Cummings J., Andreasen N., et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease: rivastigmine patch versus capsule. Int. J. Geriatr. Psychiatry 2007; 22, 456-467.
Go to original source...
Go to PubMed...
- van Dyck C. H., Tariot P. N., Meyers B., Malca Resnick E. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2007; 21, 136-143.
Go to original source...
Go to PubMed...
- Effectiveness and cost-effectiveness of acetylcholinesterase inhibitors. Downloaded from http://ageing.oxfordjournals.org/ by guest on November 17, 2014 patients with moderate-to-severe Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2007; 21, 136-143.
- Gaugler J., David R. L., Haley W. E., Mittelman M. Can counselling and support reduce Alzheimer's caregivers' burden and depressive symptoms during the transition to institutionalization? Results from the NYU caregiver intervention study. J. Am. Geriatr. Soc. 2008; 56(3), 421-428.
Go to original source...
Go to PubMed...
- Sansoni J., Vellone E., Piras G. Anxiety and depression in community-dwelling, Italian Alzheimer's disease caregivers. Int. J. Nurs. Pract. 2004; 10(2), 93-100.
Go to original source...
Go to PubMed...
- Sansoni J., Anderson K. H., Varona L. M., Varela G. Caregivers of Alzheimer's patients and factors influencing institutionalization of loved ones: some considerations on existing literature. Ann. Ig. 2013; 25, 235-246.
- Blom M. M., Bosmans J. E., Cuijpers P., Zarit S. H., Pot A. M. Effectiveness and cost-effectiveness of an internet intervention for family caregivers of people with dementia: Design of a randomized controlled trial. BMC Psychiatry 2013; 13(17), 1-7.
Go to original source...
Go to PubMed...
- Borghi A. C., de Castro V. C., Marcon S. S., Carreira L. Overload of families taking care of elderly people with Alzheimer's disease: A comparative study. Rev. Latino-Am. Enfermagern 2013; 21(4), 876-883.
Go to original source...
Go to PubMed...
- Diel L., Forster L. M. K., Kochhann R., Chaves M. L. F. Sociodemographic profile and level of burden of dementia patients' caregivers who participate in a support group. Dement. Neuropsychol. 2010; 4(3), 232-237.
Go to original source...
Go to PubMed...
- van Durme T., Macq J., Jeanmart C., Gobert M. Tools for measuring the impact of informal caregiving of the elderly: A literature review. Int. J. Nurs. Stud. 2011; 49(4), 490-504.
Go to original source...
Go to PubMed...
- Nylor M., et al. Advancing Alzheimer's diagnosis, treatment and care: Recommendations from the War Invitational Summit. Alzheimers Dement. 2012; 8(5), 445-452.
Go to original source...
Go to PubMed...
- Ivinson A. J., Lane R., May P. C., Hosford D. A., Carrillo M. C., Siemers E. R. Partnership between academia and insudtry for drug discovery in Alzheimer's disease. Alzheimer's & Dementia 2008; 4, 80-88.
Go to original source...
Go to PubMed...
- Socott, T. J., O'Connor, A. C., Link, A. N., & Beaulieu, T. J. Economic analysis of opportunities to accelerate Alzheimer's disease research and development. Ann. Y. Y. Acad. Sci. 2014; 1313, 17-34.
Go to original source...
Go to PubMed...
- Paul S. M., Mytelka D. S., Dunwiddie C. T., Persinger C. C., Munos B. H., Lindborg S. R., Schacht A. L. How to improve R & D productivity: The pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 2010; 9, 203-214.
Go to original source...
Go to PubMed...
- Karran E. Alzheimer's research U.K.: defeating dementia through research. Stem Cells Translational Medicine 2012; 1, 449-450.
Go to original source...
Go to PubMed...
- Cummings J. L., Morstorf T., Zhong K. Alzeheimer's disease drug-development pipeline: Few candidates, frequent failures. Alzeheimer's Research & Therapy 2014; 6(37), 1-7.
Go to original source...
Go to PubMed...
- Schneider L. S., et al. Clinical trials and late-stage drug development for Alzeheimer's disease: An appraisal from 1984 to 2014. Journal of Internal Medicine 2014; 275, 251-283.
Go to original source...
Go to PubMed...
- Zemek F., et al. Outcomes of Alzeheimer's disease therapy with acetylcholinesterose inhibitors and memantine. Expert Opin. Drug Saf. 2014; 13(6), 759-776.
- Korabecny J., et al. Pharmacotherapy of Alzeheimer's disease: Current state and future perspectives. Frontiers in Drug Design and Discovery 2014; 6, 702-738.
Go to original source...
- Matl O., Holmerová I., Matlová M. Zpráva o stavu demence 2014. Downloaded from http://www.alzheimer.cz/alzheimerova-choroba-v-cr/zverejnena-zprava-o-stavu-demence-2014/